Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer

Table 5 Treatment-emergent adverse events in the 85 patients of the matched dataset, n (%)

Toxicities	TP group			TB group			P value for grade 1-2	P value for grade 3-4
	Grade 0	Grade 1-2	Grade 3-4	Grade 0	Grade 1-2	Grade 3-4
	n = 55			n = 30
Anemia	37 (67.3)	17 (30.9)	1 (1.8)	21 (70.0)	7 (23.3)	2 (6.7)	0.62461	0.28332
Neutropenia	41 (74.5)	9 (16.4)	5 (9.1)	17 (56.7)	5 (16.7)	8 (26.7)	12	0.055132
Leukocytopenia	33 (60.0)	18 (32.7)	4 (7.3)	18 (60.0)	11 (36.7)	1 (3.3)	0.89921	0.65212
Thrombocytopenia	40 (72.7)	15 (27.3)	0 (0)	17 (56.7)	12 (40.0)	1 (3.3)	0.33671	0.35292
Proteinuria	39 (70.9)	16 (29.1)	0 (0)	23 (76.7)	7 (23.3)	0 (0)	0.75231	12
Aspartate transaminase increased	36 (65.5)	18 (32.7)	1 (1.8)	23 (76.7)	6 (20.0)	1 (3.3)	0.32041	12
Alanine transaminase increased	41 (74.5)	14 (25.5)	0 (0)	20 (66.7)	8 (26.7)	2 (6.7)	11	0.35292
Alkaline phosphatase increased	40 (72.7)	13 (23.6)	2 (3.6)	21 (70.0)	9 (30.0)	0 (0)	0.70321	0.53782
Blood bilirubin increased	39 (70.9)	16 (29.1)	0 (0)	24 (80.0)	5 (16.7)	1 (3.3)	0.31441	0.35292
Triglycerides increased	36 (65.5)	17 (30.9)	2 (3.6)	24 (80.0)	4 (13.3)	2 (6.7)	0.11332	0.61132
Nausea	40 (72.7)	15 (27.3)	0 (0)	23 (76.7)	6 (20.0)	1 (3.3)	0.63141	12
Vomiting	49 (89.1)	6 (10.9)	0 (0)	21 (70.0)	8 (26.7)	1 (3.3)	0.11741	0.35292
Fatigue	42 (76.4)	13 (23.6)	0 (0)	20 (66.7)	9 (30.0)	1 (3.3)	0.70321	0.35292
Fever	49 (89.1)	6 (10.9)	0 (0)	26 (86.7)	4 (13.3)	0 (0)	0.73671	12
Diarrhea	47 (85.5)	8 (14.5)	0 (0)	25 (83.4)	4 (13.3)	1 (3.3)	11	0.35292
Hypertension	48 (87.3)	6 (10.9)	1 (1.8)	24 (80.0)	3 (10.0)	3 (10.0)	12	0.12382

¹P values were calculated by χ² test.

²P values were calculated by Fisher’s exact test.

TP: Targeted therapy combined with anti-programmed cell death 1 immunotherapy; TB: Bevacizumab.